A nurse is caring for a 32-year-old female client who is 2 days postpartum in the postpartum unit.

Exhibits

For each potential client finding, click to specify if the finding is expected or unexpected.

Choice A rationale

Methylergonovine is an oxytocic medication that stimulates smooth muscle contraction of the uterus. While it can cause vasoconstriction and potentially lead to an increase in blood pressure, this is a potential side effect, not the intended therapeutic effect indicating the medication's effectiveness in the postpartum period. The primary goal is uterine contraction to control postpartum bleeding.

Choice B rationale

Breast pain is related to engorgement and milk production, not directly influenced by methylergonovine's action on the uterus. The medication's effectiveness is assessed by its impact on uterine tone and bleeding, not breast comfort. Therefore, the absence of breast pain does not indicate that the methylergonovine has been effective.

Choice C rationale

Methylergonovine is given to decrease postpartum bleeding by promoting uterine contraction, which helps to compress the blood vessels at the placental site. An increase in lochia (postpartum vaginal discharge) would suggest that the medication is not effective in achieving its intended therapeutic outcome of reducing hemorrhage.

Choice D rationale

Methylergonovine's primary therapeutic effect in the postpartum period is to stimulate uterine smooth muscle contraction, leading to a firm fundus. A firm fundus indicates that the uterus is contracting effectively, which helps to compress blood vessels at the placental site and control postpartum bleeding. This is the desired outcome of methylergonovine administration.

Rationale for Correct Condition

Preterm labor is defined as the onset of regular contractions leading to cervical change before 37 weeks of gestation. This client’s symptoms, including uterine contractions every 4–5 minutes, cervical effacement of 50%, a positive fetal fibronectin test, and shortened cervical length, strongly indicate preterm labor rather than pyelonephritis, placental abruption, or cervical insufficiency.

Rationale for Correct Actions

Magnesium sulfate functions as a tocolytic, suppressing contractions by inhibiting calcium influx in myometrial cells, thereby delaying preterm birth and reducing neonatal complications. Betamethasone accelerates fetal lung maturity by increasing surfactant production, reducing the risk of neonatal respiratory distress syndrome if preterm delivery occurs.

Rationale for Correct Parameters

Cervical effacement is a direct indicator of labor progression, showing changes in cervical thinning that accompany dilation. Monitoring effacement allows assessment of tocolytic effectiveness. Contraction frequency reveals labor severity and the response to magnesium sulfate. Persistent contractions despite treatment indicate the need for additional interventions.

Rationale for Incorrect Conditions

Pyelonephritis causes systemic symptoms like fever, flank pain, and bacteremia rather than uterine contractions and cervical changes. Placental abruption typically presents with painful vaginal bleeding and uterine tenderness, which are absent here. Cervical insufficiency is painless and lacks regular contractions, with cervical changes occurring silently rather than progressively.

Rationale for Incorrect Actions

Urine culture identifies infection but does not directly treat preterm labor. RhoGAM is necessary for Rh-negative individuals, which is irrelevant in this case. IV hydration may help with contractions but is not a primary intervention.

Rationale for Incorrect Parameters

Flank pain suggests pyelonephritis rather than preterm labor. Vaginal bleeding is associated with abruption or miscarriage, not preterm labor without cervical rupture. Fetal heart rate variability is useful in fetal assessment but does not directly indicate labor progression.